NCT02324725View on ClinicalTrials.gov

Biomarkers of Injectable Extended Release Naltrexone Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Heroin DependenceOpioid Dependence
Interventions
DRUG

Naltrexone

Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly

Trial Locations (1)

19104

Center for the Studies of Addiction, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT02324725 - Biomarkers of Injectable Extended Release Naltrexone Treatment | Biotech Hunter | Biotech Hunter